MKM Partners Upgrades Merck (MRK) to Buy
Tweet Send to a FriendGet Alerts MRK Hot Sheet
Price: $47.16 -0.36%
Rating Summary:
8 Buy, 5 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
8 Buy, 5 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade MRK Now!
MKM Partners upgraded Merck (NYSE: MRK) from Neutral to Buy with a price target of $51.00 (from $47.00).
The firm comments, "Between 2013 and 2017 we expect Merck to potentially launch 12 new products; the greatest number out of its U.S. peers. While the expected contribution from these potential launches is about average for the U.S. group, we think higher-than-average new product news flow could help Merck’s share performance over the next several years. Merck also has significantly below average patent exposure (14% of current sales) through 2017, even with the expected losses of Zetia and Vytorin in 2016. The net of these rankings implies that Merck is significantly undervalued on a forward looking basis and leads us to upgrade the company to a Buy rating."
The firm increased 2016 EPS estimate from $3.95 to $3.96 and rolling out a 2017 EPS estimate of $4.01.
For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.
Shares of Merck closed at $43.34 yesterday, with a 52 week range of $33.13-$48.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm comments, "Between 2013 and 2017 we expect Merck to potentially launch 12 new products; the greatest number out of its U.S. peers. While the expected contribution from these potential launches is about average for the U.S. group, we think higher-than-average new product news flow could help Merck’s share performance over the next several years. Merck also has significantly below average patent exposure (14% of current sales) through 2017, even with the expected losses of Zetia and Vytorin in 2016. The net of these rankings implies that Merck is significantly undervalued on a forward looking basis and leads us to upgrade the company to a Buy rating."
The firm increased 2016 EPS estimate from $3.95 to $3.96 and rolling out a 2017 EPS estimate of $4.01.
For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.
Shares of Merck closed at $43.34 yesterday, with a 52 week range of $33.13-$48.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines
- Janney Capital Boosts PT on Gap (GPS) Post Q1
- Bulls and Bears Do Battle in Aeropostale (ARO); Turnaround Intact?
Create E-mail Alert Related Categories
Analyst EPS Change, Analyst PT Change, Upgrades
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
